BNGO Stock Forecast: BioNano Genomics jumps by nearly 10% on Saphyr adoption in U.K. labs
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:BNGO added 9.85% on Wednesday as the broader markets enjoyed a rare day in the green.
- BioNano’s Saphyr system has been adopted by two major labs in the U.K. which are owned by NHS.
- BNGO is ramping up its development as it plans to release the prototype for its next generation of Saphyr later this year.
Update April 24: BioNano Genomics Inc (NASDAQ: BNGO) shares have kicked off Thursday's session with an increase of nearly 10% to around $6.50. As detailed below, the gene-related company is venturing into the British market and that provides fresh prospects for higher incomes. The gains recorded on Thursday complete a third consecutive day of gains after BNGO shares lost ground throughout most of April.
NASDAQ:BNGO was a Wall Street darling in 2020, as the company based out of San Diego, California was pegged by many to be one of the next big genomics stocks to buy. But since BioNano’s Saphyr platform stole the show at the Cytogenomics symposium earlier this year, shares have nosedived losing nearly 60% of its price. On Wednesday BioNano gained 9.85% to close the trading session at $5.91, as the broader markets rallied following weeks of choppiness.
Stay up to speed with hot stocks' news!
The main catalyst for BioNano’s surge was the announcement that its Saphyr genome mapping platform has been adopted in two major U.K. labs that belong to the National Health System. The agency is using Saphyr to accurately map the genomes of patients with conditions such as heme malignancies, developmental delay, infertility, and other potential genetic diseases. These are just the latest cases of a successful year for Saphyr, which saw its sales grow year over year from 73 in 2019 to 97 in 2020. BioNano has already given guidance for 2021 sales and it expects another rise in Saphyr sales from 97 to 150.
BNGO Stock news
As the original Saphyr platform is ramping up, BioNano has already announced that the next-generation version will have a prototype ready by the end of 2021. It is anticipated that the updated version will be capable of handling fourteen times the amount of genomes analyzed and should revolutionize the way that pediatric and prenatal health can be monitored, right from birth.
- NASDAQ:BNGO added 9.85% on Wednesday as the broader markets enjoyed a rare day in the green.
- BioNano’s Saphyr system has been adopted by two major labs in the U.K. which are owned by NHS.
- BNGO is ramping up its development as it plans to release the prototype for its next generation of Saphyr later this year.
Update April 24: BioNano Genomics Inc (NASDAQ: BNGO) shares have kicked off Thursday's session with an increase of nearly 10% to around $6.50. As detailed below, the gene-related company is venturing into the British market and that provides fresh prospects for higher incomes. The gains recorded on Thursday complete a third consecutive day of gains after BNGO shares lost ground throughout most of April.
NASDAQ:BNGO was a Wall Street darling in 2020, as the company based out of San Diego, California was pegged by many to be one of the next big genomics stocks to buy. But since BioNano’s Saphyr platform stole the show at the Cytogenomics symposium earlier this year, shares have nosedived losing nearly 60% of its price. On Wednesday BioNano gained 9.85% to close the trading session at $5.91, as the broader markets rallied following weeks of choppiness.
Stay up to speed with hot stocks' news!
The main catalyst for BioNano’s surge was the announcement that its Saphyr genome mapping platform has been adopted in two major U.K. labs that belong to the National Health System. The agency is using Saphyr to accurately map the genomes of patients with conditions such as heme malignancies, developmental delay, infertility, and other potential genetic diseases. These are just the latest cases of a successful year for Saphyr, which saw its sales grow year over year from 73 in 2019 to 97 in 2020. BioNano has already given guidance for 2021 sales and it expects another rise in Saphyr sales from 97 to 150.
BNGO Stock news
As the original Saphyr platform is ramping up, BioNano has already announced that the next-generation version will have a prototype ready by the end of 2021. It is anticipated that the updated version will be capable of handling fourteen times the amount of genomes analyzed and should revolutionize the way that pediatric and prenatal health can be monitored, right from birth.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.